Atyr PHARMA's (ATYR) "Buy" Rating Reaffirmed at HC Wainwright

Atyr PHARMA (NASDAQ:ATYR - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $35.00 price target on the stock.

Several other analysts have also recently commented on the stock. Jefferies Financial Group began coverage on shares of Atyr PHARMA in a research note on Thursday, September 5th. They issued a "buy" rating and a $9.00 price objective for the company. Wells Fargo & Company began coverage on shares of Atyr PHARMA in a research note on Friday, October 4th. They issued an "overweight" rating and a $17.00 price objective for the company. Finally, Royal Bank of Canada restated an "outperform" rating and set a $16.00 target price on shares of Atyr PHARMA in a research report on Wednesday, August 14th.

Atyr PHARMA Stock Performance

Atyr PHARMA stock remained flat at $3.32 during midday trading on Tuesday. 1,158,526 shares of the company's stock traded hands, compared to its average volume of 560,657. Atyr PHARMA has a 52 week low of $1.08 and a 52 week high of $3.68. The company has a current ratio of 7.63, a quick ratio of 7.63 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $229.12 million, a PE ratio of -4.04 and a beta of 1.21. The business's 50-day moving average is $2.11.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. Research analysts anticipate that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.